MOCLOBEMIDE (AURORIX) IN PRIMARY MAJOR DEPRESSION

1. Moclobemide (Aurorix) is a newly developed, effective, short-acting well tolerable and safe antidepressant wich belongs to the new class of reversible monoamine oxidase-A inhibitors. 2. Aurorix was given per os in an open clinical trial for 6 weeks to 30 patients with DSM-III diagnoses of (nonpsychotic, nonmelancholic) major depression. 3. Out o f the 25 patients who completed the study 14 (56%) were responders and 11 (44%) non-responders. 4. The patients tolerated the drug very well , and no serious side-effects were noted. 5. Pretreatment biological m arkers (dexamethasone suppression test, platelet-MAO-B activity, 3H-im ipramine binding, thyroid function) did not have a predictive value re garding the drug response.